Antipsychotic Agents – Antipsychotic Injectable Agents

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS Maximum Days' Supply Allowed	PR – Enrollment in a Physician- Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana 1-855-242-0802
AmeriHealth Caritas Louisiana 1-800-684-5502
Fee-for-Service (FFS) Louisiana Legacy Medicaid 1-866-730-4357
Healthy Blue 1-844-521-6942
Louisiana Healthcare Connections 1-888-929-3790
UnitedHealthcare 1-800-310-6826

Antipsychotic Agents – Antipsychotic Injectable Agents

POS Edits

BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for all agents when requested for recipients who are younger than 7 years of age.

DX – Pharmacy claims for all agents must be submitted with an appropriate diagnosis code found at <u>THIS LINK</u>.

		Generic – Brand Example	Maximum Dose for 18 Years of Age and Older
MD – Some agents have a maximum daily dose as listed in the chart to the right.		Aripiprazole – Aristada®	1064mg
		Paliperidone – Invega Trinza®	819mg
		Risperidone – Perseris [™]	120mg
PU – These agents require evidence in pharmacy claims indicating established tolerance with previous use of an oral or injectable form.	Generic (Brand Example)	Claim for At Least a 14-Day Supply of Oral in Previous 30-Day Period	Number of Injectable Claims in Previous Period of Time
	Aripiprazole (Abilify Maintena®) Aripiprazole (Aristada®) Aripiprazole (Aristada Initio®)	Aripiprazole	ONE claim for ANY aripiprazole injectable product in the previous 365 days
	Olanzapine (Zyprexa Relprevv®)	Olanzapine	ONE claim for Zyprexa Relprevv® in the previous 365 days
	Paliperidone (Invega Sustenna®)	Paliperidone or Risperidone	ONE claim for any risperidone injectable product OR Invega Sustenna® in the previous 365 days
	Paliperidone (Invega Trinza®)	N/A	FOUR claims for Invega Sustenna® in the previous 120-day period OR ONE claim for Invega Trinza® in the previous 365 days
	Risperidone (Risperdal Consta®)	Risperidone	ONE claim for Risperdal Consta® in previous 365 days
	Risperidone (Perseris TM)	Risperidone	ONE claim for Risperdal Consta® OR Perseris® in the previous 365 days
	Medication		Quantity Limit
	Abilify Maintena®		1 unit every 28 days
	Aristada® 441mg; 662mg; 882mg syringe		1 unit every 28 days
\mathbf{QL} – Some	Aristada® 1064mg syringe		1 unit every 56 days
agents have	Aristada [®] Initio [™] 675mg syringe		Limited to 1 unit per 18-month period
	quantity limits as Invega Sustenna®		1 unit every 28 days
listed in the chart	Invega Trinza®		1 unit per rolling 90 days
to the right.	Perseris™		1 unit every 28 days
	Risperdal Consta®		2 units every 28 days
	Zyprexa Relprevv [®] 210mg & 300mg		2 units every 28 days
	Zyprexa Relprevv® 405mg s are monitored at the pharmacy POS for duplication of therapy with each		1 unit every 28 days

Antipsychotic Agents – Antipsychotic Injectable Agents

Revision / Date	Implementation Date
Created POS Document	February 2020
Modified to apply new age requirement for behavioral health clinical authorization / September 2020	January 2021